The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
Open accessAbstract
Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current therapies. Here we report a completed phase I trial evaluating IL-13Rα2-targeted CAR-T cells in 65 patients with recurrent high-grade glioma, the majority being recurrent glioblastoma (rGBM). Primary objectives were safety and feasibility, maximum tolerated dose/maximum feasible dose and a recommended phase 2 dose plan. Secondary objectives included overall survival, disease response, cytokine dynamics and tumor immune contexture biomarkers. This trial evolved to evaluate three routes of locoregional T cell administration (intratumoral (ICT), intraventricular (ICV) and dual ICT/ICV) and two manufacturing platforms, culminating in arm 5, which utilized dual ICT/ICV delivery and an optimized manufacturing process. Locoregional CAR-T cell administration was feasible and well tolerated, and as there were no dose-limiting toxicities across all arms, a maximum tolerated dose was not determined. Probable treatment-related grade 3+ toxicities were one grade 3 encephalopathy and one grade 3 ataxia. A clinical maximum feasible dose of 200 × 10 6 CAR-T cells per infusion cycle was achieved for arm 5; however, other arms either did not test or achieve this dose due to manufacturing feasibility. A recommended phase 2 dose will be refined in future studies based on data from this trial. Stable disease or better was achieved in 50% (29/58) of patients, with two partial responses, one complete response and a second complete response after additional CAR-T cycles off protocol. For rGBM, median overall survival for all patients was 7.7 months and for arm 5 was 10.2 months. Central nervous system increases in inflammatory cytokines, including IFNγ, CXCL9 and CXCL10, were associated with CAR-T cell administration and bioactivity. Pretreatment intratumoral CD3 T cell levels were positively associated with survival. These findings demonstrate that locoregional IL-13Rα2-targeted CAR-T therapy is safe with promising clinical activity in a subset of patients. ClinicalTrials.gov Identifier: NCT02208362 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Integrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
Yushkevich, P. A., Piven, J., Hazlett, H. C., Smith, R. G., Ho, S., Gee, J. C., & Gerig, G. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.015 · Cited by 8,868
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Self-citationO’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Multiplexed droplet single-cell RNA-sequencing using natural genetic variation
Kang, H. M., Subramaniam, M., Targ, S., Nguyen, M., Maliskova, L., McCarthy, E., Wan, E., Wong, S., Byrnes, L., Lanata, C. M., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4042 · Cited by 1,101
Li, H., van der Leun, A. M., Yofe, I., Lubling, Y., Gelbard-Solodkin, D., van Akkooi, A. C. J., van den Braber, M., Rozeman, E. A., Haanen, J. B. A. G., Blank, C. U., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.043 · Cited by 1,101
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063
Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862
Ahmed, N., Brawley, V., Hegde, M., Bielamowicz, K., Kalra, M., Landi, D., Robertson, C., Gray, T. L., Diouf, O., Wakefield, A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0184 · Cited by 850
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., et al. (2022) · Nature · doi:10.1038/s41586-022-04489-4 · Cited by 823
Donnelly, M. L. L., Luke, G., Mehrotra, A., Li, X., Hughes, L. E., Gani, D., & Ryan, M. D. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-5-1013 · Cited by 798
Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J., Wright, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0428 · Cited by 764
Self-citationThe Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Petitprez, F., Meylan, M., de Reyniès, A., Sautès-Fridman, C., & Fridman, W. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00784 · Cited by 602
Deng, Q., Han, G., Puebla-Osorio, N., Ma, M. C. J., Strati, P., Chasen, B., Dai, E., Dang, M., Jain, N., Yang, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1061-7 · Cited by 600
Self-citationWang, X., Chang, W.-C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600
Self-citationXie, J., & Liu, C. (2005) · Statistics in Medicine · doi:10.1002/sim.2174 · Cited by 510
Alizadeh, D., Wong, R. A., Yang, X., Wang, D., Pecoraro, J. R., Kuo, C.-F., Aguilar, B., Qi, Y., Ann, D. K., Starr, R., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0466 · Cited by 453
Self-citationKmiecik, J., Poli, A., Brons, N. H. C., Waha, A., Eide, G. E., Enger, P. Ø., Zimmer, J., & Chekenya, M. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.08.013 · Cited by 389
Goff, S. L., Morgan, R. A., Yang, J. C., Sherry, R. M., Robbins, P. F., Restifo, N. P., Feldman, S. A., Lu, Y.-C., Lu, L., Zheng, Z., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000260 · Cited by 377
Kahlon, K. S., Brown, C., Cooper, L. J. N., Raubitschek, A., Forman, S. J., & Jensen, M. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0454 · Cited by 368
Self-citationSimon, M. J., & Iliff, J. J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.014 · Cited by 342
Wang, X., Popplewell, L. L., Wagner, J. R., Naranjo, A., Blanchard, M. S., Mott, M. R., Norris, A. P., Wong, C. W., Urak, R. Z., Chang, W.-C., et al. (2016) · Blood · doi:10.1182/blood-2015-12-686725 · Cited by 322
Self-citationVitanza, N. A., Johnson, A. J., Wilson, A. L., Brown, C., Yokoyama, J. K., Künkele, A., Chang, C. A., Rawlings-Rhea, S., Huang, W., Seidel, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01404-8 · Cited by 321
Self-citationT-cell Dysfunction in Glioblastoma: Applying a New Framework
Woroniecka, K. I., Rhodin, K. E., Chongsathidkiet, P., Keith, K. A., & Fecci, P. E. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0047 · Cited by 315
Challenges in glioblastoma research: focus on the tumor microenvironment
Bikfalvi, A., da Costa, C. A., Avril, T., Barnier, J.-V., Bauchet, L., Brisson, L., Cartron, P. F., Castel, H., Chevet, E., Chneiweiss, H., et al. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2022.09.005 · Cited by 302
Brown, C. E., Aguilar, B., Starr, R., Yang, X., Chang, W.-C., Weng, L., Chang, B., Sarkissian, A., Brito, A., Sanchez, J. F., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.002 · Cited by 299
Self-citationVitanza, N. A., Wilson, A. L., Huang, W., Seidel, K., Brown, C., Gustafson, J. A., Yokoyama, J. K., Johnson, A. J., Baxter, B. A., Koning, R. W., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0750 · Cited by 279
Self-citationDistinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
Haradhvala, N. J., Leick, M. B., Maurer, K., Gohil, S. H., Larson, R. C., Yao, N., Gallagher, K. M. E., Katsis, K., Frigault, M. J., Southard, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01959-0 · Cited by 271
Arcangeli, S., Bove, C., Mezzanotte, C., Camisa, B., Falcone, L., Manfredi, F., Bezzecchi, E., El Khoury, R., Norata, R., Sanvito, F., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci150807 · Cited by 251
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
Good, Z., Spiegel, J. Y., Sahaf, B., Malipatlolla, M. B., Ehlinger, Z. J., Kurra, S., Desai, M. H., Reynolds, W. D., Wong Lin, A., Vandris, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01960-7 · Cited by 248
CXCL9 and CXCL10 bring the heat to tumors
Reschke, R., & Gajewski, T. F. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq6509 · Cited by 226
Zah, E., Nam, E., Bhuvan, V., Tran, U., Ji, B. Y., Gosliner, S. B., Wang, X., Brown, C. E., & Chen, Y. Y. (2020) · Nature Communications · doi:10.1038/s41467-020-16160-5 · Cited by 222
Self-citationBoulch, M., Cazaux, M., Loe-Mie, Y., Thibaut, R., Corre, B., Lemaître, F., Grandjean, C. L., Garcia, Z., & Bousso, P. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd4344 · Cited by 218
CAR T cells for brain tumors: Lessons learned and road ahead
Akhavan, D., Alizadeh, D., Wang, D., Weist, M. R., Shepphird, J. K., & Brown, C. E. (2019) · Immunological Reviews · doi:10.1111/imr.12773 · Cited by 214
Self-citationTumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Scholler, N., Perbost, R., Locke, F. L., Jain, M. D., Turcan, S., Danan, C., Chang, E. C., Neelapu, S. S., Miklos, D. B., Jacobson, C. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01916-x · Cited by 212
Sex Steroid Hormone Receptors in Human Thymoma
Ishibashi, H., Suzuki, T., Suzuki, S., Moriya, T., Kaneko, C., Takizawa, T., Sunamori, M., Handa, M., Kondo, T., & Sasano, H. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021353 · Cited by 211
Chen, G. M., Chen, C., Das, R. K., Gao, P., Chen, C.-H., Bandyopadhyay, S., Ding, Y.-Y., Uzun, Y., Yu, W., Zhu, Q., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1677 · Cited by 207
Jonnalagadda, M., Mardiros, A., Urak, R., Wang, X., Hoffman, L. J., Bernanke, A., Chang, W.-C., Bretzlaff, W., Starr, R., Priceman, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.208 · Cited by 204
Self-citationTreatment options for progression or recurrence of glioblastoma: a network meta-analysis
McBain, C. A., Lawrie, T. A., Rogozińska, E., Kernohan, A., Robinson, T., & Jefferies, S. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013579.pub2 · Cited by 189
Gorlia, T., Stupp, R., Brandes, A. A., Rampling, R. R., Fumoleau, P., Dittrich, C., Campone, M. M., Twelves, C. C., Raymond, E., Hegi, M. E., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.004 · Cited by 186
CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival
Yang, I., Tihan, T., Han, S. J., Wrensch, M. R., Wiencke, J., Sughrue, M. E., & Parsa, A. T. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.03.031 · Cited by 181
IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity
Alizadeh, D., Wong, R. A., Gholamin, S., Maker, M., Aftabizadeh, M., Yang, X., Pecoraro, J. R., Jeppson, J. D., Wang, D., Aguilar, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1661 · Cited by 170
Self-citationGlioma IL13Rα2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis
Brown, C. E., Warden, C. D., Starr, R., Deng, X., Badie, B., Yuan, Y.-C., Forman, S. J., & Barish, M. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077769 · Cited by 166
Self-citationOff-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma
Brown, C. E., Rodriguez, A., Palmer, J. M., Ostberg, J. R., Naranjo, A., Wagner, J. R., Aguilar, B., Starr, R., Weng, L., Synold, T. W., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac024 · Cited by 166
Self-citationPET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89Zr-Oxine
Weist, M. R., Starr, R., Aguilar, B., Chea, J., Miles, J. K., Poku, E., Gerdts, E., Yang, X., Priceman, S. J., Forman, S. J., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.206714 · Cited by 159
Self-citationDebinski, W., & Gibo, D. M. (2000) · Molecular Medicine · doi:10.1007/bf03401786 · Cited by 142
Wang, X., Naranjo, A., Brown, C. E., Bautista, C., Wong, C. W., Chang, W.-C., Aguilar, B., Ostberg, J. R., Riddell, S. R., Forman, S. J., et al. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318270dec7 · Cited by 140
Self-citationClinical Evaluation of a Fully-automatic Segmentation Method for Longitudinal Brain Tumor Volumetry
Meier, R., Knecht, U., Loosli, T., Bauer, S., Slotboom, J., Wiest, R., & Reyes, M. (2016) · Scientific Reports · doi:10.1038/srep23376 · Cited by 130
Zhu, Y., Hubbard, R. A., Chubak, J., Roy, J., & Mitra, N. (2021) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5338 · Cited by 120
Jaén, M., Martín‐Regalado, Á., Bartolomé, R. A., Robles, J., & Casal, J. I. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188802 · Cited by 73
Landi, D. B., Ahmed, N. M., Gottschalk, S. M., et al. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/wy57-0z30 · Cited by 69
Aldoss, I. T., Khaled, S. K., Wang, X., Palmer, J. M., Wang, Y., Wagner, J. R., Clark, M. C., Simpson, J., Paul, J. A., Vyas, V., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2038 · Cited by 67
Self-citationWang, X., Huynh, C., Urak, R. Z., Weng, L., Walter, M., Lim, L., Vyas, V., Chang, W.-C., Aguilar, B., Brito, A., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0236 · Cited by 47
Self-citationSystemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
Portnow, J., Wang, D., Blanchard, M. S., Tran, V., Alizadeh, D., Starr, R., Dodia, R., Chiu, V., Brito, A., Kilpatrick, J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4508 · Cited by 46
Self-citationClinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature
Tipping, M. D., Eickhoff, J. C., & Robins, H. I. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.06.070 · Cited by 30
Immunologic Features in De Novo and Recurrent Glioblastoma Are Associated with Survival Outcomes
Alanio, C., Binder, Z. A., Chang, R. B., Nasrallah, M. P., Delman, D., Li, J. H., Tang, O. Y., Zhang, L. Y., Zhang, J. V., Wherry, E. J., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-1050 · Cited by 26
Starr, R., Aguilar, B., Gumber, D., Maker, M. S., Huard, S. M., Wang, D., Chang, W.-C., Brito, A., Chiu, V., Ostberg, J. R., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0185 · Cited by 17
Self-citationPopplewell, L. L., Wang, X., Blanchard, S., Wagner, J. R., Naranjo, A., Adria, A., Paul, J. A., Lim, L., Chang, W.-C., Budde, L. E., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119650 · Cited by 13
Self-citationLarson, S. M., Walthers, C. M., Ji, B., Ghafouri, S. N., Naparstek, J., Trent, J., Harris, C. M., Khericha, M., Schweppe, T., Auerbach, M. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.2543 · Cited by 12
Potency monitoring of CAR T cells
Wang, D., Yang, X., Xella, A., Stern, L. A., & Brown, C. E. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2022.07.010 · Cited by 9
Self-citation
Cited by
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 373
Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Liu, Y., Zhou, F., Ali, H., Lathia, J. D., & Chen, P. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01226-x · Cited by 336
Du, B., Qin, J., Lin, B., Zhang, J., Li, D., & Liu, M. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.019 · Cited by 254
Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms
Chang, C., Chavarro, V. S., Gerstl, J. V. E., Blitz, S. E., Spanehl, L., Dubinski, D., Valdes, P. A., Tran, L. N., Gupta, S., Esposito, L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126733 · Cited by 45
Metadata
- Authors
- Brown, C. E., Hibbard, J. C., Alizadeh, D., Blanchard, M. S., Natri, H. M., Wang, D., Ostberg, J. R., Aguilar, B., Wagner, J. R., Paul, J. A., Starr, R., Wong, R. A., Chen, W., Shulkin, N., Aftabizadeh, M., Filippov, A., Chaudhry, A., Ressler, J. A., Kilpatrick, J., Myers-McNamara, P., Chen, M., Wang, L. D., Rockne, R. C., Georges, J., Portnow, J., Barish, M. E., D’Apuzzo, M., Banovich, N. E., Forman, S. J., & Badie, B.
- Venue
- Nature Medicine
- Published
- 2024-03-07
- Volume
- 30
- Issue
- 4
- Pages
- 1001-1012
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4392560879
- Cited by
- 345
- References
- 68
- FWCI
- 52.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.